论文部分内容阅读
目的探讨参麦注射液配合常规治疗冠状动脉粥样硬化性心脏病的疗效和安全性。方法选择2014年2月~2015年1月在本单位进行治疗的90例冠状动脉粥样硬化性心脏病患者,随机分为观察组和对照组各45例,两组患者均给予调血脂、抗血小板以及ACEI等常规治疗,观察组在对照组的基础上给予参麦注射液,7d为一个疗程,比较两组疗效以及不良反应情况。结果观察组总有效率(95.56%)明显高于对照组(73.33%)(χ2=8.46,P<0.05);观察组ST段下移和T波倒置程度均显著低于治疗前(P<0.05),且明显低于对照组(P<0.05);两组均无明显不良发应(P>0.05)。结论本研究表明,参麦注射液联合常规治疗动脉粥样硬化性心脏病是有效的,安全性高,可推广应用。
Objective To investigate the efficacy and safety of Shenmai injection in combination with conventional treatment of coronary heart disease. Methods From September 2014 to January 2015, 90 patients with coronary atherosclerotic heart disease who were treated in this unit were randomly divided into observation group and control group, 45 cases in each group. Both groups were given blood lipid, Platelets and ACEI and other conventional treatment, the observation group was given Shenmai injection on the basis of the control group, 7d for a course of treatment, the two groups were compared efficacy and adverse reactions. Results The total effective rate (95.56%) in the observation group was significantly higher than that in the control group (73.33%) (χ2 = 8.46, P <0.05) ), Which was significantly lower than that of the control group (P <0.05). There was no significant adverse reaction between the two groups (P> 0.05). Conclusion This study shows that Shenmai injection combined with conventional treatment of atherosclerotic heart disease is effective, safe, and can be extended.